Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EVOLENCE
- Development stage
- Unknown
- Lead developer
- Johnson & Johnson
- Modality
- Recombinant Proteins and Enzymes, Device-based Delivery → Drug Delivery Systems
- Administration
- Subcutaneous, Intradermal (injection)
01
Overview
DP101 is referenced in the context of a clinical study titled "DP101-US-04," which was an open-label, multi-center, prospective, post-market study to assess the safety and effectiveness of EVOLENCE in facial augmentation for subjects with Fitzpatrick Skin Color Types IV, V, and VI. Based on this information, "DP101" appears to be a code name for EVOLENCE used during clinical development. EVOLENCE is an injectable dermal filler composed of porcine collagen cross-linked with D-ribose sugar. It is used for soft tissue augmentation to correct moderate-to-deep facial wrinkles and folds such as nasolabial folds.
- Brand names
- EVOLENCE
Beyond the preview
Go deeper on EVOLENCE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EVOLENCE.